Tilorone confers robust in vitro and in vivo antiviral effects against severe fever with thrombocytopenia syndrome virus

  • Virol Sin. 2022 Feb;37(1):145-148. doi: 10.1016/j.virs.2022.01.014.
Jingjing Yang  1 ,  Yunzheng Yan  2 ,  Qingsong Dai  2 ,  Jiye Yin  2 ,  Lei Zhao  2 ,  Yuexiang Li  2 ,  Wei Li  2 ,  Wu Zhong  2 ,  Ruiyuan Cao  3 ,  Song Li  4
Affiliations
  • 1. School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China; National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
  • 2. National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
  • 3. National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Electronic address: [email protected].
  • 4. School of Pharmaceutical Sciences, Hainan University, Haikou, 570228, China; National Engineering Research Centre for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Electronic address: [email protected].
PMID: 35234618 DOI: 10.1016/j.virs.2022.01.014
Abstract

  1. •

    Tilorone dihydrochloride possesses robust anti-SFTSV activity in vitro and in vivo.

  2. •

    Intraperitoneal administration of tilorone leads to protection against intracranial lethal challenge of SFTSV.

  3. •

    The anti-SFTSV mechanism of tilorone is through stimulation of host innate immunity.

  4. •

    Pre-treatment with tilorone can prevent mice from lethal SFTSV challenge.

Products